CORVUS PHARMACEUTICALS INC (CRVS) Stock Analyst Ratings
USA - NASDAQ:CRVS - US2210151005 - Common Stock
8.185 USD
+0.02 (+0.18%)
ChartMill assigns a Buy % Consensus number of 86% to CRVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 15.3. This target is 86.93% above the current price.
CRVS was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CRVS.
In the previous month the buy percentage consensus was at a similar level.
CRVS was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-05-20 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2025-03-26 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-02 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-13 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-09-16 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2024-05-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-01 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-03-27 | Mizuho | Maintains | Neutral -> Neutral |
| 2024-03-20 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-16 | Mizuho | Reiterate | Neutral -> Neutral |
| 2023-05-30 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2023-05-09 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-30 | Mizuho | Reiterate | Neutral |
| 2022-10-07 | Ladenburg Thalmann | Initiate | Buy |
| 2021-12-03 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-12-01 | Jefferies | Initiate | Buy |
| 2021-08-03 | Mizuho | Maintains | Neutral |
| 2021-07-16 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-27 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-03-26 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-10 | Mizuho | Downgrade | Buy -> Neutral |
CORVUS PHARMACEUTICALS INC / CRVS FAQ
What is the price target for CRVS stock?
13 analysts have analysed CRVS and the average price target is 15.3 USD. This implies a price increase of 86.93% is expected in the next year compared to the current price of 8.185.
What is the consensus rating for CRVS stock?
The consensus rating for CORVUS PHARMACEUTICALS INC (CRVS) is 86.1538 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for CORVUS PHARMACEUTICALS INC stock?
The number of analysts covering CORVUS PHARMACEUTICALS INC (CRVS) is 13.